Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Radiation Sterilization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    120 result(s) found for: Radiation Sterilization. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2013-001296-20 Sponsor Protocol Number: MITOCET Start Date*: 2013-12-20
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Randomized Phase IV Trial to Compare Cetuximab with Concomitant Radiation Therapy with Concomitant Mitomycin-C and 5-FU with Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of The H...
    Medical condition: Locally advanced squamous cell carcinomas of head and neck
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004758-39 Sponsor Protocol Number: ESR-18-13485 Start Date*: 2019-06-12
    Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA
    Full Title: A PHASE II STUDY OF CAPECITABINE PLUS CONCOMITANT RADIATION THERAPY FOLLOWED BY DURVALUMAB (MEDI4736) AS PREOPERATIVE TREATMENT IN RECTAL CANCER
    Medical condition: Locally advanced (T3-4 N0-1) rectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038019 Rectal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001045-40 Sponsor Protocol Number: GEM-1805 Start Date*: 2020-03-03
    Sponsor Name:Grupo Español Multidisciplinar de Melanoma
    Full Title: Phase II, Open-Label Study of preliminary efficacy of Durvalumab (MEDI4736) in Combination with Cediranib in Patients with Metastatic Uveal Melanoma
    Medical condition: Metastatic uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001409-34 Sponsor Protocol Number: MO39171 Start Date*: 2017-11-20
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL C...
    Medical condition: Malignant neoplasm of bronchus and lung (nsc) adv.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) SE (Completed) DK (Completed) LV (Completed) PL (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Ongoing) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004064-62 Sponsor Protocol Number: SNOXA12C401 Start Date*: 2019-05-07
    Sponsor Name:TME Pharma AG
    Full Title: Single-arm, dose-escalation Phase 1/2 Study of olaptesed pegol (NOX-A12) in combination with irradiation in inoperable or partially resected first-line glioblastoma patients with unmethylated MGMT ...
    Medical condition: glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000577-36 Sponsor Protocol Number: S60379 Start Date*: 2018-08-27
    Sponsor Name:University Hospitals Leuven
    Full Title: Durvalumab (MEDI4736) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity study
    Medical condition: resectable, locally advanced squamous cell carcinoma of the oral cavity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001203-32 Sponsor Protocol Number: DEDALUS Start Date*: 2021-10-25
    Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
    Full Title: An open-label, multi-center, phase 2 study of chemo-immunotherapy followed by reduced-dose hypo-fractionated RT and maintenance immunotherapy for stage III unresectable Non –small-cell lung carcino...
    Medical condition: stage III unresectable non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002264-27 Sponsor Protocol Number: ENGOT-ov54/Swiss-GO-2/MATAO Start Date*: 2021-03-17
    Sponsor Name:Swiss GO Trial Group
    Full Title: MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO) including LOGOS ...
    Medical condition: Patients with low and high grade serous and endometrioid ovarian cancer patients.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002827-15 Sponsor Protocol Number: A3671009 Start Date*: 2006-01-19
    Sponsor Name:Pfizer Ltd. [...]
    1. Pfizer Ltd.
    2.
    Full Title: Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma
    Medical condition: Advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    8.0 10025650 VTc
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) AT (Completed) BE (Completed) SE (Completed) GR (Completed) CZ (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003916-29 Sponsor Protocol Number: TREASURE Start Date*: 2020-06-25
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    Full Title: - TREASURE- Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease: a randomized, open-label, multicenter phase II study
    Medical condition: Small cell lung cancer extensive disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004742-42 Sponsor Protocol Number: IFCT-1802 Start Date*: 2019-08-29
    Sponsor Name:IFCT
    Full Title: A phase II single-arm trial evaluating safety and efficacy of Durvalumab in ECOG Performance Status 2-3, treatment-naive, patients with stage IV Non-Small Cell Lung Cancer (NSCLC) and high PD-L1 t...
    Medical condition: Patient with a non small cell lung cancer and a poor general status
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.1 100000004867 10057364 Reduced general condition LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001388-55 Sponsor Protocol Number: CAPT Start Date*: 2020-02-24
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: A Phase II Trial of atezolizumab plus carboplatin plus paclitaxel as first-line therapy in metastatic Triple-negative PD-L1 positive breast cancer patients
    Medical condition: Metastatic Triple-negative PD-L1 positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073100 Metaplastic breast carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002453-38 Sponsor Protocol Number: 15-102-14 Start Date*: 2017-01-17
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been...
    Medical condition: Metastatic breast cancer with stable brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) CZ (Completed) BE (Completed) PT (Completed) FR (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001438-16 Sponsor Protocol Number: OBI-822-011 Start Date*: 2022-01-25
    Sponsor Name:OBI Pharma, Inc.
    Full Title: The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H...
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002620-26 Sponsor Protocol Number: INCB18424-268 Start Date*: 2014-12-22
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
    Medical condition: Metastatic or advanced HER-2 negative breast cancer patients who have already received treatment with anthracyclines and paclitaxel.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended) PT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-003306-32 Sponsor Protocol Number: 030(Z)WO19247 Start Date*: 2021-01-18
    Sponsor Name:Angelini Pharma S.p.A.
    Full Title: Phase IV study on the feasibility of a preventative/therapeutic approach with Benzydamine Oromucosal solution in radiation-induced Oral Mucositis (OM) in patients with head and neck cancer (HNC)
    Medical condition: Oral Mucositis (OM) in patients with head and neck cancer (HNC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10056468 Oral mucosal disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003389-26 Sponsor Protocol Number: RG14-093 Start Date*: 2015-01-12
    Sponsor Name:University of Birmingham
    Full Title: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
    Medical condition: Oropharyngeal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031096 Oropharyngeal cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted) IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005537-32 Sponsor Protocol Number: D419QC00007 Start Date*: 2021-07-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Ca...
    Medical condition: Extensive-stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) BG (Ongoing) IT (Ongoing) CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004835-56 Sponsor Protocol Number: GEMCAD-1703 Start Date*: 2019-08-13
    Sponsor Name:Grupo español mutidisciplinar en cáncer digestivo (GEMCAD)
    Full Title: Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer
    Medical condition: Locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001270-24 Sponsor Protocol Number: A3671014 Start Date*: 2007-02-13
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: Phase 2, single arm study of ticilimumab in patients with refractory metastatic adenocarcinoma of the colon or rectum
    Medical condition: Refractory meatstatic adenocarcinoma of the colon or rectum
    Disease: Version SOC Term Classification Code Term Level
    8,0 10061289 VTc
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:01:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA